Literature DB >> 28229945

Patients' appropriateness, acceptability, usability and preferences for pharmaceutical preparations: Results from a literature review on clinical evidence.

Nélio Drumond1, Diana A van Riet-Nales2, Fatma Karapinar-Çarkit3, Sven Stegemann4.   

Abstract

Patients play an important role in achieving the desired therapeutic outcomes, as they are frequently responsible for their own medication management. To facilitate drug administration and overcome medication issues, the patients' needs and preferences should be considered in the pharmaceutical drug product design. With the aim to evaluate the current state of evidence for patient appropriateness, acceptability, usability and preference for aspects of this design, a literature search was performed. Comparative clinical studies that assessed such endpoints for different patient populations were included and summarized descriptively. The search identified 45 publications that met the inclusion criteria. A detailed analysis of the studies identified two main areas investigating either packaging design (n=10) or dosage form design (n=35). Studies on packaging design showed preferences for wing top and screw cap openings, push-through blisters and suppositories with slide system. Additionally, child-resistant containers should be avoided concerning specific patient populations. Regarding dosage form design, sprinkles and minitablets were the most preferred in studies involving young patients, while preferences varied considerably depending on route of administration and geographical region in studies with adult patients. Review of the methodology used in the studies revealed that ten studies had used well-defined protocols and observational endpoints to investigate patient appropriateness. Studies focusing on methodology for testing the appropriateness and usability of drug products by patients were not found. In conclusion, more interdisciplinary scientific efforts are required to develop and increase research in understanding patient needs and preferences.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acceptability; Appropriateness; Dosage form design; Drug product; Packaging design; Pharmaceutical development; Preference

Mesh:

Substances:

Year:  2017        PMID: 28229945     DOI: 10.1016/j.ijpharm.2017.02.029

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  12 in total

1.  A Decision Support Tool Facilitating Medicine Design for Optimal Acceptability in The Older Population.

Authors:  Thibault Vallet; Emilie Belissa; Sandra Laribe-Caget; Alain Chevallier; François-Xavier Chedhomme; Patrick Leglise; Matthieu Piccoli; Hugues Michelon; Vanessa Bloch; Sylvie Meaume; Anne-Sophie Grancher; Nathalie Bachalat; Imad Boulaich; Fattima Abdallah; Maite Rabus; Jean-Paul Rwabihama; Annie-Claude Ribemont; Celia Lachuer; Ines Perquy; Laurent Lechowski; Anne Delahaye; Mathieu Depoisson; Yann Orven; Caroline Guinot; Stephane Gibaud; Corinne Michel; Abdel Mahiou; Sid-Ahmed Belbachir; Jean-Hugues Trouvin; Amelie Dufaÿ-Wojcicki; Vincent Boudy; Fabrice Ruiz
Journal:  Pharm Res       Date:  2018-05-07       Impact factor: 4.200

2.  Dosage form suitability in vulnerable populations: A focus on paracetamol acceptability from infants to centenarians.

Authors:  Fabrice Ruiz; Thibault Vallet; Amélie Dufaÿ Wojcicki; Émilie Belissa; Jean-Eudes Fontan; Loïc de Pontual; Sylvie Nathanson; Alain Chevallier; Sandra Laribe-Caget; Vincent Boudy
Journal:  PLoS One       Date:  2019-08-20       Impact factor: 3.240

3.  An Investigation into the Relationship between Xanthan Gum Film Coating Materials and Predicted Oro-Esophageal Gliding Performance for Solid Oral Dosage Forms.

Authors:  Nélio Drumond; Sven Stegemann
Journal:  Pharmaceutics       Date:  2020-12-20       Impact factor: 6.321

4.  Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation.

Authors:  Atoya Adams; Charles Barish; Angel Chen; Patrick Dennis; Richard Krause; Peter Lichtlen; Taryn Losch-Beridon; Shadreck Mareya; Jeffrey Schneider
Journal:  Adv Ther       Date:  2021-04-08       Impact factor: 3.845

Review 5.  Recent Advances in Polymer-Based Vaginal Drug Delivery Systems.

Authors:  Tomasz Osmałek; Anna Froelich; Barbara Jadach; Adam Tatarek; Piotr Gadziński; Aleksandra Falana; Kinga Gralińska; Michał Ekert; Vinam Puri; Joanna Wrotyńska-Barczyńska; Bozena Michniak-Kohn
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321

6.  Standardised evaluation of medicine acceptability in paediatric population: reliability of a model.

Authors:  Thibault Vallet; Fabrice Ruiz; Marc Lavarde; Anne-Marie Pensé-Lhéritier; Ameziane Aoussat
Journal:  J Pharm Pharmacol       Date:  2017-10-26       Impact factor: 3.765

7.  Comparison of Different Liquid and Semisolid Vehicles Selected for Oral Administration of Pellets and Minitablets with Diazepam: In Vitro Investigation.

Authors:  Hanna Kotlowska; Marta Szymanska; Malgorzata Sznitowska
Journal:  AAPS PharmSciTech       Date:  2020-07-31       Impact factor: 3.246

8.  Requests for new oral antibiotic prescriptions in children within 2 days: a Norwegian population-based study.

Authors:  E H Bergene; H Nordeng; T B Rø; A Steinsbekk
Journal:  Fam Pract       Date:  2018-12-12       Impact factor: 2.267

Review 9.  Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence.

Authors:  Enrica Menditto; Valentina Orlando; Giuseppe De Rosa; Paola Minghetti; Umberto Maria Musazzi; Caitriona Cahir; Marta Kurczewska-Michalak; Przemysław Kardas; Elísio Costa; José Manuel Sousa Lobo; Isabel F Almeida
Journal:  Pharmaceutics       Date:  2020-01-03       Impact factor: 6.321

10.  Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis.

Authors:  Georg Griesinger; Christophe Blockeel; Elke Kahler; Claire Pexman-Fieth; Jan I Olofsson; Stefan Driessen; Herman Tournaye
Journal:  PLoS One       Date:  2020-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.